Researchers Call for State-Led Medical Marijuana Research Centers Following Federal Rescheduling
- Researchers argue that states with established medical marijuana programs should create independent research centers to close evidence gaps, standardize data, and facilitate cannabis integration into healthcare after federal rescheduling to Schedule III.
- A century of prohibition and restrictive policies limited cannabis research, but states with mature medical markets and strong healthcare infrastructure are well positioned to lead cannabis science through government-authorized, politically independent research centers.
- These centers would centralize patient and product data, standardize documentation of outcomes and adverse events, and generate real-world evidence on medical marijuana’s therapeutic effects, safety, and healthcare implementation.
- The proposal requires enabling legislation, sustained funding, and partnerships across stakeholders, emphasizing that research must remain independent from policymaking to ensure science, not politics, drives future cannabis policies.
(Photo credit: Brock University).
States with established medical marijuana programs should create independent research centers to close evidence gaps, standardize data and help integrate cannabis into healthcare following federal rescheduling, researchers argue in Clinical Therapeutics.
The authors argue that a century of prohibition and restrictive international policies has limited scientific research even as medical marijuana programs have expanded rapidly. Federal marijuana rescheduling to Schedule III could reduce some research barriers, but they say states are particularly well positioned to lead the next phase of cannabis science.
States with mature medical markets and strong healthcare, biotechnology and academic infrastructure could establish research centers authorized by the government but protected from political interference, according to the commentary.
These centers could centralize patient and product data, standardize how outcomes and adverse events are documented and generate real-world evidence on marijuana’s therapeutic effects, safety and implementation in healthcare settings.
The proposal would require enabling legislation, sustained funding and partnerships among researchers, healthcare providers, patients, regulators and the marijuana industry.
The authors also emphasize that research should remain independent from policymaking and regulation, allowing scientific findings rather than political priorities to guide conclusions.
Cannabis has been used medicinally for thousands of years, but the authors say modern prohibition created substantial gaps in clinical knowledge and contributed to an inconsistent patchwork of state policies and healthcare practices.
They conclude that state-led research could help develop a more unified scientific framework for medical marijuana while informing national policy following federal rescheduling.
“It is time for medical cannabis to move beyond the nonscientific narratives that historically drove excessively restrictive US policies and global control treaties,” the authors said, arguing that future policy should instead be based on scientific evidence and clinical need.